Drug intelligence / Profile preview

EU501

Development stage: Preclinical
Lead developer: Eutilex
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EU501 is a bispecific monoclonal antibody targeting both human HER2 and 4-1BB (CD137). It is designed for the treatment of HER2-positive solid cancers. The drug aims to enhance tumor cell-specific killing with low side effects and demonstrates improved efficacy in tumor clearance compared to monospecific antibodies. By engaging both HER2 on tumor cells and 4-1BB on immune cells, EU501 is intended to stimulate a potent anti-tumor immune response while minimizing off-target toxicity. The drug is currently in non-clinical (preclinical) development by Eutilex[1].

Targets

TNFRSF9 (CD137 extracellular domain)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on EU501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EU501.

Explore the full profile